Item 2.02. Results of Operations and Financial Condition.

The January 9, 2023, Jazz Pharmaceuticals plc (the "Company") J.P. Morgan Healthcare Conference presentation includes a corporate overview and financial update, as well as the Company's expectations that it will meet its previously announced total, neuroscience and oncology revenue guidance ranges for the year ended December 31, 2022. A copy of the presentation is attached hereto as Exhibit 99.1.

The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 of this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits

Exhibit
Number       Description

99.1           Presentation slides by Jazz Pharmaceuticals plc on January 9, 2023

104          Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses